secwatch.observer — SEC 8-K summary
======================================

Issuer:     OptimizeRx Corp (OPRX)
CIK:        0001448431
Form:       8-K
Filed at:   2026-06-05T20:10:29+00:00
Accession:  0001213900-26-065810
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

OptimizeRx CCO Theresa Greco to depart June 15; advisory role through June 2027
-------------------------------------------------------------------------------

- Greco's separation effective June 15, 2026; she will serve as advisor through June 15, 2027.
- She receives 12 months' base salary continuation at $380,000/yr, a $209,000 lump sum bonus target, and COBRA reimbursement for 12 months.
- Equity grants continue to vest during the 12-month advisory term; change-of-control special bonus preserved.
- Greco subject to 12-month non-compete and non-solicit obligations under Business Protection Agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1448431/000121390026065810/0001213900-26-065810-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1448431/000121390026065810/ea0293598-8k_optimize.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-065810

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer